中国再生医学2025中期报告

中國再生醫學國際有限公司 INTERIM REPORT
中 期 報 告 CHARACTERISTICS OF GEM (“GEM”) OF THESTOCK EXCHANGE OF HONG KONG LIMITED (THE“STOCK EXCHANGE”) 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）之特點 GEM之定位乃為相比其他在聯交所上市之公司帶有較高投資風險之中小型公司提供一個上市之市場。有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決定。 GEM has been positioned as a market designed toaccommodate small and mid-sized companies towhich a higher investment risk may be attachedthan other companies listed on the Stock Exchange.Prospective investors should be aware of thepotential risks of investing in such companies andshould make the decision to invest only after dueand careful consideration. 由於GEM上市之公司普遍為中小型公司，在GEM買賣之證券可能會較在主板買賣之證券承受較大之市場波動風險，同時無法保證在GEM買賣之證券會有高流通量之市場。 Given that the companies listed on GEM aregenerally small and mid-sized companies, there isa risk that securities traded on GEM may be moresusceptible to high market volatility than securitiestraded on the Main Board and no assurance is giventhat there will be a liquid market in the securitiestraded on GEM. 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本報告全部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 Hong Kong Exchanges and Clearing Limited and theStock Exchange take no responsibility for the contentsof this report, make no representation as to its accuracyor completeness and expressly disclaim any liabilitywhatsoever for any loss howsoever arising from or inreliance upon the whole or any part of the contents of thisreport. 本報告旨在遵照聯交所GEM證券上市規則（「GEM上市規則」）之規定，提供有關中國再生醫學國際有限公司（「本公司」）及其附屬公司（統稱為「本集團」）之資料。本公司董事（「董事」）對此共同及個別承擔全部責任。董事在作出一切合理查詢後確認，就彼等所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何其他事項，足以令致本報告或其所載任何陳述產生誤導。 This report, for which the directors (the “Directors”)of China Regenerative Medicine International Limited(the “Company”) collectively and individually accept fullresponsibility, includes particulars given in compliancewith the Rules Governing the Listing of Securities onGEM of the Stock Exchange (the “GEM Listing Rules”)for the purpose of giving information with regard to theCompany and its subsidiaries (collectively the “Group”).The Directors, having made all reasonable enquiries,confirm that to the best of their knowledge and beliefthe information contained in this report is accurate andcomplete in all material respects and not misleading ordeceptive, and there are no other matters the omissionof which would make any statement herein or this reportmisleading. CONTENTS 公司資料3 簡明綜合損益及6其他全面收入表 簡明綜合財務狀況表8簡明綜合權益變動表10簡明綜合現金流量表12簡明綜合財務報表附註13 管理層討論及分析27 其他資料32 本中期報告之中文翻譯如有任何錯漏，應以英文為準。 In the event of any error or omission in the Chinesetranslation of this interim report, the English text shallprevail. CORPORATE INFORMATION DIRECTORS 執行董事 Executive Director 王闖先生（董事會主席兼行政總裁） Mr. Wang Chuang(Chairman of the Board andChief Executive Officer) 非執行董事雒敏女士（於二零二五年四月二十五日獲委任） Non-executive DirectorMs. Luo Min(appointed on 25/4/2025) 獨立非執行董事 Independent Non-executive Directors 梁文輝先生霍春玉女士周旭東先生（於二零二五年六月三十日獲委任）劉明博士（於二零二五年六月三十日辭任） Mr. Leung Man FaiMs. Huo ChunyuMr. Zhou Xudong(appointed on 30/6/2025)Dr. Liu Ming(resigned on 30/6/2025) COMPANY SECRETARY 陳樂彤女士（於二零二五年六月三十日獲委任）黃寶田先生（於二零二五年四月二十五日辭任） Ms. Chan Lok Tung(appointed on 30/6/2025)Mr. Wong Po Tin(resigned on 25/4/2025) NOMINATION COMMITTEE 周旭東先生（提名委員會主席）（於二零二五年六月三十日獲委任）梁文輝先生霍春玉女士劉明博士（於二零二五年六月三十日辭任） Mr. Zhou Xudong(chairman of Nomination Committee)(appointed on 30/6/2025) Mr. Leung Man FaiMs. Huo ChunyuDr. Liu Ming(resigned on 30/6/2025) REMUNERATION COMMITTEE 周旭東先生（薪酬委員會主席）（於二零二五年六月三十日獲委任）霍春玉女士梁文輝先生劉明博士（於二零二五年六月三十日辭任） Mr. Zhou Xudong(chairman of Remuneration Committee)(appointed on 30/6/2025) Ms. Huo ChunyuMr. Leung Man FaiDr. Liu Ming(resigned on 30/6/2025) AUDIT COMMITTEE 梁文輝先生（審核委員會主席）霍春玉女士周旭東先生（於二零二五年六月三十日獲委任）劉明博士（於二零二五年六月三十日辭任） Mr. Leung Man Fai(chairman of Audit Committee)Ms. Huo ChunyuMr. Zhou Xudong(appointed on 30/6/2025) Dr. Liu Ming(resigned on 30/6/2025) REGISTERED OFFICE Cricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Cricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands HEAD OFFICE ANDPRINCIPAL PLACE OF BUSINESSIN HONG KONG 香港九龍尖沙咀彌敦道132號美麗華大廈2310–2318室 Suite 2310–2318, Miramar Tower132 Nathan RoadTsim Sha Tsui, KowloonHong Kong 王闖先生 COMPLIANCE OFFICERMr. Wang Chuang AUTHORISED REPRESENTATIVES 王闖先生陳樂彤女士（於二零二五年六月三十日獲委任）黃寶田先生（於二零二五年四月二十五日辭任） Mr. Wang ChuangMs. Chan Lok Tung(appointed on 30/6/2025) Mr. Wong Po Tin(resigned on 25/4/2025) PRINCIPAL BANKERS 香港上海滙豐銀行有限公司恒生銀行有限公司大新銀行有限公司江南農村商業銀行中國工商銀行中國銀行（香港）有限公司 Hong Kong and Shanghai Banking Corporation LimitedHang Seng Bank LimitedDah Sing Bank LimitedJiangnan Rural Commercial BankIndustrial and Commercial Bank of ChinaBank of China (Hong Kong) Limited AUDITOR 金道連城會計師事務所有限公司香港尖沙咀河內道5號普基商業中心20樓2001–02室 Linksfield CPA LimitedUnit 2001–02, 20/F., Podium Plaza5 Hanoi Road, Tsim Sha TsuiHong Kong LEGAL ADVISERS 有關開曼群島法律：Conyers Dill & Pearman香港中環康樂廣場8號交易廣場第一座29樓有關香港法律：競天公誠律師事務所有限法律責任合夥香港皇后大道中15號置地廣場公爵大廈32樓3203–3207室 As to